Lupin gets Chinese regulator's nod for influenza drug Oseltamivir Phosphate
This story was originally published at 16:53 IST on 22 May 2026
Register to read our real-time news.Informist, Friday, May 22, 2026
--Lupin gets Chinese health body nod for Oseltamivir Phosphate
MUMBAI – Lupin Ltd. Friday said it has received approval from China's National Medical Products Administration for its abbreviated new drug application for the influenza drug Oseltamivir Phosphate. This marks Lupin's first product entry into China, the company said in an exchange filing.
Lupin filed the abbreviated new drug application in partnership with China's Yabao Pharmaceuticals. Oseltamivir Phosphate for oral suspension will be made available for pediatric use in a concentration of 6 mg/ml.
For the March quarter, Lupin reported a consolidated net profit of INR 14.60 billion on revenues of INR 74.75 billion. Friday, the pharmaceutical company's shares closed 0.1% lower at INR 2,281.80 on the National Stock Exchange. End
Reported by Ruchira Kagita
Edited by Saji George Titus
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (22) 6985-4000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
